As the neuro-oncology community reflects on the advancements of the past year and looks toward upcoming clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the focus has shifted from standard empirical treatments toward high-precision, multiomic strategies. CancerNetwork spoke with Sonikpreet Aulakh, MBBS, MD, an assistant professor of Translational NeuroOncology in the Department of Medical Oncology and physician-scientist at West Virginia University, about the top data to watch for at the ASCO Annual Meeting. In the discussion, Aulakh highlighted data emerging in tumor microenvironment (TME) reprogramming, the clinical necessity of personalized maintenance for patients with glioblastoma, and the foundational role of multidisciplinary collaboration.
